ABVC BioPharma, Inc. (NasdaqCM: ABVC)
Health Care · Biotechnology · US
$0.84
-5.61% today · -69.6% 1Y
ABVC BioPharma, Inc. (NasdaqCM: ABVC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.07M and employs 18 people.
Over the last twelve months the share price has lost 69.6%, trading between 0.82 and 3.40.
Tweenvest scores ABVC BioPharma, Inc. across four factors: quality 16/100. Its strongest factor is quality.
ABVC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.07M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.29
- Dividend yield
- —
- Beta (5Y)
- 0.63
- 52-week high
- $3.40
- 52-week low
- $0.82
- Avg volume (3M)
- —
- Shares outstanding
- 25.92M
- Employees
- 18
- Next earnings
- —
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
- ISIN
- US00091F3047
- Listed since
- Nov 10, 2004
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.